> Accueil  >  Innovations et recherche  >  Les publications

Les publications indexées dans pubmed #


PUBLICATIONS 2015

Lire la suite


 

Muren, LP ; Jornet, N ; Georg, D ; Garcia, R ; Thwaites, DI , Improving radiotherapy through medical physics developments., Radiother Oncol, 2015, 117, 403-6


 
Damiola, F ; Schultz, I ; Barjhoux, L ; Sornin, V ; Dondon, MG ; Eon-Marchais, S & al , Mutation analysis of PALB2 gene in French breast cancer families., Breast Cancer Res Treat, 2015, 154, 463-71


 
Moureau-Zabotto, L ; Gal, J ; Resbeut, M ; Mineur, L ; Teissier, √Č ; H√©buterne, X & al , [Management and clinical outcome in patients over 80 years with rectal cancer treated between 2006 and 2008 in Southern France (PACA region)]., Cancer Radiother, 2015, 19, 725-32


 
Trojan, J ; Mineur, L ; Tom√°?ek, J ; Rouleau, E ; Fabian, P ; de Maglio, G & al , Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review., PLoS One, 2015, 10, e0140717


 
Debourdeau, P ; Meuleman, C ; Dufaitre, G ; Laroche, JP ; Slama, B ; Chebrek, S & al , [Methods of development of recommendations for clinical practice (RCP) and of setting-up of a platform cancer heart vessels (PTF-CHV) in the inter3C Vaucluse-Arles]., Bull Cancer, 2015, 102, 932-9


 
Pourel, N ; Meyrieux-Croset, C ; Isambert, A , [Experience feedback committees (CREX) and beyond?]., Cancer Radiother, 2015, 19, 624-8


 
Rousse, C ; Chauvet, B , [Recommendations for inspections of the French nuclear safety authority]., Cancer Radiother, 2015, 19, 634-7


 
Farge, D ; Trujillo-Santos, J ; Debourdeau, P ; Bura-Riviere, A ; Rodriguez-Beltr√°n, EM ; Nieto, JA & al , Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism., Medicine (Baltimore), 2015, 94, e1235


 
Sicre de Fontbrune, F ; Moignet, A ; Beaupain, B ; Suarez, F ; Galicier, L ; Socié, G & al , Severe chronic primary neutropenia in adults: report on a series of 108 patients., Blood, 2015, 126, 1643-50


 
Ouaissi, M ; Frasconi, C ; Mege, D ; Panicot-Dubois, L ; Boiron, L ; Dahan, L & al , Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma., Hepatobiliary Pancreat Dis Int, 2015, 14, 436-42


 
Le Péchoux, C ; Dunant, A ; Faivre-Finn, C ; Thomas, PA ; Pourel, N ; Lerouge, D & al , Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence., J Clin Oncol, 2015, 33, 2930-1


 
Tabernero, J ; Lenz, HJ ; Siena, S ; Sobrero, A ; Falcone, A ; Ychou, M & al , Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial., Lancet Oncol, 2015, 16, 937-48


 
Vincent, J ; Mariette, C ; Pezet, D ; Huet, E ; Bonnetain, F ; Bouché, O & al , Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone., Eur J Cancer, 2015, 51, 1683-93


 
Zhu, AX ; Park, JO ; Ryoo, BY ; Yen, CJ ; Poon, R ; Pastorelli, D & al , Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial., Lancet Oncol, 2015, 16, 859-70


 
Garcia, R ; Nyström, H ; Fiorino, C ; Thwaites, D , Does a too risk-averse approach to the implementation of new radiotherapy technologies delay their clinical use?, Br J Radiol, 2015, 88, 20150124


 
Blein, S ; Bardel, C ; Danjean, V ; McGuffog, L ; Healey, S ; Barrowdale, D & al , An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers., Breast Cancer Res, 2015, 17, 61


 
Hebbar, M ; Chibaudel, B ; André, T ; Mineur, L ; Smith, D ; Louvet, C & al , FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial., Ann Oncol, 2015, 26, 1040


 
Machiels, JP ; Haddad, RI ; Fayette, J ; Licitra, LF ; Tahara, M ; Vermorken, JB & al , Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial., Lancet Oncol, 2015, 16, 583-94


 
Schulman, S ; Zondag, M ; Linkins, L ; Pasca, S ; Cheung, YW ; de Sancho, M & al , Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis., J Thromb Haemost, 2015, 13, 1010-8


 
Blanco, I ; Kuchenbaecker, K ; Cuadras, D ; Wang, X ; Barrowdale, D ; de Garibay, GR & al , Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers., PLoS One, 2015, 10, e0120020


 
Lecarpentier, J ; Noguès, C ; Mouret-Fourme, E ; Buecher, B ; Gauthier-Villars, M ; Stoppa-Lyonnet, D & al , Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers., Cancer Epidemiol Biomarkers Prev, 2015, 24, 698-707


 
Kuchenbaecker, KB ; Ramus, SJ ; Tyrer, J ; Lee, A ; Shen, HC ; Beesley, J & al , Identification of six new susceptibility loci for invasive epithelial ovarian cancer., Nat Genet, 2015, 47, 164-71


 
Hebbar, M ; Chibaudel, B ; André, T ; Mineur, L ; Smith, D ; Louvet, C & al , FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial., Ann Oncol, 2015, 26, 340-7


 
Kalinka-Warzocha, E ; Plazas, JG ; Mineur, L ; Salek, T ; Hendlisz, A ; DeCosta, L & al , Chemotherapy treatment patterns and neutropenia management in gastric cancer., Gastric Cancer, 2015, 18, 360-7
 
 


 

PUBLICATIONS 2016

Lire la suite


Ricotta, R ; Verrioli, A ; Ghezzi, S ; Porcu, L ; Grothey, A ; Falcone, A & al , Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)., ESMO Open, 2016, 1, e000111




Delaloge, S ; Bachelot, T ; Bidard, FC ; Espie, M ; Brain, E ; Bonnefoi, H & al , [Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]]., Bull Cancer, 2016, 103, 951-952




Karthaus, M ; Hofheinz, RD ; Mineur, L ; Letocha, H ; Greil, R ; Thaler, J & al , Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer., Br J Cancer, 2016, 115, 1215-1222




Farge, D ; Bounameaux, H ; Brenner, B ; Cajfinger, F ; Debourdeau, P ; Khorana, AA & al , International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer., Lancet Oncol, 2016, 17, e452-e466




Cautela, J ; Lalevée, N ; Ammar, C ; Ederhy, S ; Peyrol, M ; Debourdeau, P & al , Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives., Int J Cardiol, 2016, 224, 366-375




Reddy, R ; Nguyen, NM ; Sarrabay, G ; Rezaei, M ; Rivas, MC ; Kavasoglu, A & al , The genomic architecture of NLRP7 is Alu rich and predisposes to disease-associated large deletions., Eur J Hum Genet, 2016, 24, 1516




Pourel, N , [Radiotherapy for small cell lung carcinoma]., Cancer Radiother, 2016, 20, 547-57




de Crevoisier, R ; Duvergé, L ; Hulot, C ; Chauvet, B ; Henry, O ; Bouvet, C & al , [Interest of positioning control in onboard imaging and its delegation to the therapists]., Cancer Radiother, 2016, 20, 601-7




Lawrenson, K ; Kar, S ; McCue, K ; Kuchenbaeker, K ; Michailidou, K ; Tyrer, J & al , Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus., Nat Commun, 2016, 7, 12675




Mège, A ; Ziouèche-Mottet, A ; Bodez, V ; Garcia, R ; Arnaud, A ; de Rauglaudre, G & al , [Respiratory synchronization and breast radiotherapy]., Cancer Radiother, 2016, 20, 576-82




Hamadou, WS ; Bourdon, V ; Létard, S ; Brenet, F ; Laarif, S ; Besbes, S & al , Familial hematological malignancies: new IDH2 mutation., Ann Hematol, 2016, 95, 1943-1947




de Crevoisier, R ; Chauvet, B ; Barillot, I ; Lafond, C ; Mahé, M ; Delpon, G , [Image-guided radiotherapy]., Cancer Radiother, 2016, 20 Suppl, S27-35




Pourel, N ; Meyrieux, C ; Perrin, B , [Quality and safety management for radiotherapy]., Cancer Radiother, 2016, 20 Suppl, S20-6




Hennequin, C ; Barillot, I ; Azria, D ; Belkacémi, Y ; Bollet, M ; Chauvet, B & al , [Radiotherapy of breast cancer]., Cancer Radiother, 2016, 20 Suppl, S139-46




Mahé, MA ; Barillot, I ; Chauvet, B , [Guidelines for external radiotherapy and brachytherapy: 2nd edition]., Cancer Radiother, 2016, 20 Suppl, S4-7




Riou, O ; Chauvet, B ; Lagrange, JL ; Martin, P ; Llacer Moscardo, C ; Charissoux, M & al , [Radiotherapy of bladder cancer]., Cancer Radiother, 2016, 20 Suppl, S196-9




de Crevoisier, R ; Pommier, P ; Latorzeff, I ; Chapet, O ; Chauvet, B ; Hennequin, C , [Prostate cancer external beam radiotherapy]., Cancer Radiother, 2016, 20 Suppl, S200-9




No√ęl, G ; Antoni, D ; Barillot, I ; Chauvet, B , [Delineation of organs at risk and dose constraints]., Cancer Radiother, 2016, 20 Suppl, S36-60




Barillot, I ; Chauvet, B ; Hannoun Lévi, JM ; Lisbona, A ; Leroy, T ; Mahé, MA , [The irradiation process]., Cancer Radiother, 2016, 20 Suppl, S8-S19




Delaloge, S ; Bachelot, T ; Bidard, FC ; Espie, M ; Brain, E ; Bonnefoi, H & al , [Breast cancer screening: On our way to the future]., Bull Cancer, 2016, 103, 753-63




Adenis, A ; de la Fouchardiere, C ; Paule, B ; Burtin, P ; Tougeron, D ; Wallet, J & al , Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program., BMC Cancer, 2016, 16, 518




Lefevre, JH ; Mineur, L ; Kotti, S ; Rullier, E ; Rouanet, P ; de Chaisemartin, C & al , Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)., J Clin Oncol, 2016, 34, 3773-3780




Vernerey, D ; Huguet, F ; Vienot, A ; Goldstein, D ; Paget-Bailly, S ; Van Laethem, JL & al , Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)., Br J Cancer, 2016, 115, 281-9




Adenis, A ; de la Fouchardiere, C ; Paule, B ; Burtin, P ; Tougeron, D ; Wallet, J & al , Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program., BMC Cancer, 2016, 16, 412




Bibault, JE ; Morelle, M ; Perrier, L ; Pommier, P ; Boisselier, P ; Coche-Dequéant, B & al , Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer., Cancer Radiother, 2016, 20, 357-61




Cajfinger, F ; Debourdeau, P ; Lamblin, A ; Benatar, V ; Falvo, N ; Benhamou, Y & al , Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study., Thromb Res, 2016, 144, 85-92




Cutuli, B ; Tunon De Lara, C ; Arnaud, A ; Bertheau, P ; Boulanger, L ; Boute, V & al , [Ductal carcinoma in situ diagnosis: 3 French national guidelines]., Ann Pathol, 2016, 36, 166-73




Cohen, AT ; Harrington, RA ; Goldhaber, SZ ; Hull, RD ; Wiens, BL ; Gold, A & al , Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients., N Engl J Med, 2016, 375, 534-44




Loret, EP ; Darque, A ; Jouve, E ; Loret, EA ; Nicolino-Brunet, C ; Morange, S & al , Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial., Retrovirology, 2016, 13, 35




Hammel, P ; Huguet, F ; van Laethem, JL ; Goldstein, D ; Glimelius, B ; Artru, P & al , Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial., JAMA, 2016, 315, 1844-53




Perrier, L ; Morelle, M ; Pommier, P ; Boisselier, P ; Coche-Dequeant, B ; Gallocher, O & al , Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer., Int J Radiat Oncol Biol Phys, 2016, 95, 654-62




Hamadou, WS ; Bourdon, V ; Gaildrat, P ; Besbes, S ; Fabre, A ; Youssef, YB & al , Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies., Ann Hematol, 2016, 95, 1043-50




Bonnefoi, H ; Grellety, T ; Tredan, O ; Saghatchian, M ; Dalenc, F ; Mailliez, A & al , A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)., Ann Oncol, 2016, 27, 812-8




Arnaud, A ; Dumuids, M ; Mège, A ; de Rauglaudre, G ; Regis Arnaud, A ; Martin, N & al , ["SOS SEIN 84" accelerated breast disease management: Patients satisfaction survey]., Bull Cancer, 2016, 103, 415-20




Loret, EP ; Darque, A ; Jouve, E ; Loret, EA ; Nicolino-Brunet, C ; Morange, S & al , Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial., Retrovirology, 2016, 13, 21




Reddy, R ; Nguyen, NM ; Sarrabay, G ; Rezaei, M ; Rivas, MC ; Kavasoglu, A & al , The genomic architecture of NLRP7 is Alu rich and predisposes to disease-associated large deletions., Eur J Hum Genet, 2016, 24, 1445-52




Crochet, P ; Molinari, N ; Darmon, JC ; Cutuli, B ; Serin, D , Follow-up of Patients Treated for pT1aN0M0 Breast Cancer: 10-year Survival and Prognostic Factors., Breast J, 2016, 22, 363-5




Lledo, G ; Huguet, F ; Chibaudel, B ; Di Fiore, F ; Mineur, L ; Galais, MP & al , Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX., Eur J Cancer, 2016, 56, 115-121




Khemissa, F ; Mineur, L ; Amsellem, C ; Assenat, E ; Ramdani, M ; Bachmann, P & al , A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm., Dig Liver Dis, 2016, 48, 327-32




Taieb, J ; Zaanan, A ; Le Malicot, K ; Julié, C ; Blons, H ; Mineur, L & al , Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial., JAMA Oncol, 2016, 2, 643-653




Sinilnikova, OM ; Dondon, MG ; Eon-Marchais, S ; Damiola, F ; Barjhoux, L ; Marcou, M & al , GENESIS: a French national resource to study the missing heritability of breast cancer., BMC Cancer, 2016, 16, 13




Phelip, JM ; Mineur, L ; De la Fouchardière, C ; Chatelut, E ; Quesada, JL ; Roblin, X & al , High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT)., Ann Surg Oncol, 2016, 23, 2161-6




Forbes, JF ; Sestak, I ; Howell, A ; Bonanni, B ; Bundred, N ; Levy, C & al , Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial., Lancet, 2016, 387, 866-73




Janoray, G ; Pointreau, Y ; Garaud, P ; Chapet, S ; Alfonsi, M ; Sire, C & al , Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ¬Ī Docetaxel for Larynx Preservation., J Natl Cancer Inst, 2016, 108,




De Sainte Marie, B ; Mallet, S ; Gaudy-Marqueste, C ; Baumstarck, K ; Bentaleb, N ; Loundou, A & al , [Therapeutic failure in scabies: An observational study]., Ann Dermatol Venereol, 2016, 143, 9-15




du Bois, A ; Kristensen, G ; Ray-Coquard, I ; Reuss, A ; Pignata, S ; Colombo, N & al , Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet Oncol, 2016, 17, 78-89




Robb, WB ; Messager, M ; Dahan, L ; Mornex, F ; Maillard, E ; D''''Journo, XB & al , Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone., Br J Surg, 2016, 103, 117-25




Hamadou, WS ; Abed, RE ; Besbes, S ; Bourdon, V ; Fabre, A ; Youssef, YB & al , Familial hematological malignancies: ASXL1 gene investigation., Clin Transl Oncol, 2016, 18, 385-90




Guy, JB ; Falk, AT ; Auberdiac, P ; Cartier, L ; Vallard, A ; Ollier, E & al , Dosimetric study of volumetric arc modulation with RapidArc and intensity-modulated radiotherapy in patients with cervical cancer and comparison with 3-dimensional conformal technique for definitive radiotherapy in patients with cervical cancer., Med Dosim, 2016, 41, 9-14




 

PUBLICATIONS 2017

Lire la suite


de Nonneville, A ; Toullec, C ; Blay, JY ; Ranchere, D ; Stoeckle, PE ; Italiano, A & al , Patients with primary localized high-grade sarcomas of the digestive tract excluding GIST : a retrospective study from the French sarcoma group., Acta Gastroenterol Belg, 2017, 80, 481-486




Han van Krieken, J ; Kafatos, G ; Bennett, J ; Mineur, L ; Tom√°?ek, J ; Rouleau, E & al , Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review., BMC Cancer, 2017, 17, 798




Debourdeau, P ; Espié, M ; Chevret, S ; Gligorov, J ; Elias, A ; Dupré, PF & al , Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study., Cancer Med, 2017, 6, 2732-2744




Azria, D ; Doyen, J ; Jarlier, M ; Martel-Lafay, I ; Hennequin, C ; Etienne, P & al , Late toxicities and clinical outcome at 5?years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer., Ann Oncol, 2017, 28, 2436-2442




Gallo, M ; Mineur, L ; Emptas, H ; Costes, V ; Ramos, J , [Hepatic myelolipoma: A rare entity, case report and review of the literature]., Ann Pathol, 2017, 37, 415-419




Blais, E ; Pichon, B ; Mampuya, A ; Antoine, M ; Lagarde, P ; Kantor, G & al , [Lung dose constraints for normo-fractionated radiotherapy and for stereotactic body radiation therapy]., Cancer Radiother, 2017, 21, 584-596




Antonia, SJ ; Villegas, A ; Daniel, D ; Vicente, D ; Murakami, S ; Hui, R & al , Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer., N Engl J Med, 2017, 377, 1919-1929




Pourroy, B ; Letellier, C ; Helvig, A ; Chanet, B ; De Crozals, F ; Alessandra, C , Development of a rapid risk evaluation tool for herbs/drugs interactions in cancer patients: a multicentric experience in south of France., Eur J Cancer Care (Engl), 2017, 26,




Bibault, JE ; Dussart, S ; Pommier, P ; Morelle, M ; Huguet, M ; Boisselier, P & al , Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis., Int J Radiat Oncol Biol Phys, 2017, 99, 929-937




Hamadou, WS ; Mani, R ; Besbes, S ; Bourdon, V ; Youssef, YB ; Eisinger, F & al , GATA2 gene analysis in several forms of hematological malignancies including familial aggregations., Ann Hematol, 2017, 96, 1635-1639




Tao, Y ; Aupérin, A ; Graff, P ; Lapeyre, M ; Grégoire, V ; Maingon, P & al , Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials., Oral Oncol, 2017, 71, 61-66




Emile, JF ; Julié, C ; Le Malicot, K ; Lepage, C ; Tabernero, J ; Mini, E & al , Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX., Eur J Cancer, 2017, 82, 16-24




Pineton de Chambrun, M ; Luyt, CE ; Beloncle, F ; Gousseff, M ; Mauhin, W ; Argaud, L & al , The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission., Crit Care Med, 2017, 45, 1216-1223




Pineton de Chambrun, M ; Gousseff, M ; Mauhin, W ; Lega, JC ; Lambert, M ; Rivière, S & al , Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome., Am J Med, 2017, 130, 1219.e19-1219.e27




von Minckwitz, G ; Procter, M ; de Azambuja, E ; Zardavas, D ; Benyunes, M ; Viale, G & al , Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer., N Engl J Med, 2017, 377, 122-131




Vinant, P ; Joffin, I ; Serresse, L ; Grabar, S ; Jaulmes, H ; Daoud, M & al , Integration and activity of hospital-based palliative care consultation teams: the INSIGHT multicentric cohort study., BMC Palliat Care, 2017, 16, 36




Kerbrat, P ; Desmoulins, I ; Roca, L ; Levy, C ; Lortholary, A ; Marre, A & al , Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)., Eur J Cancer, 2017, 79, 166-175




Pougnet, I ; Jaegle, E ; Garcia, R ; Tessier, F ; Faivre, JC ; Louvel, G & al , [Spinal stereotactic body radiotherapy: French assessment in 2016]., Cancer Radiother, 2017, 21, 276-285




Denis, F ; Lethrosne, C ; Pourel, N ; Molinier, O ; Pointreau, Y ; Domont, J & al , Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients., J Natl Cancer Inst, 2017, 109,




Crétel-Durand, E ; Nouguerède, E ; Le Caer, H ; Rousseau, F ; Retornaz, F ; Guillem, O & al , PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: study protocol for a randomized controlled trial., Trials, 2017, 18, 174




Bachet, JB ; Hammel, P ; Desramé, J ; Meurisse, A ; Chibaudel, B ; André, T & al , Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial., Lancet Gastroenterol Hepatol, 2017, 2, 337-346




Bonetto, R ; Tallet, A ; Mélot, A ; Calderon, B ; Barlesi, F , [The management of bone metastasis]., Bull Cancer, 2017, 104, 585-592




Rolland, B ; Bouhassira, D ; Authier, N ; Auriacombe, M ; Martinez, V ; Polomeni, P & al , [Misuse and dependence on prescription opioids: Prevention, identification and treatment]., Rev Med Interne, 2017, 38, 539-546




Dranitsaris, G ; Shane, LG ; Galanaud, JP ; Stemer, G ; Debourdeau, P ; Woodruff, S , Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria., Support Care Cancer, 2017, 25, 2093-2102




Faure, M ; Niccoli, P ; Autret, A ; Cavaglione, G ; Mineur, L ; Raoul, JL , Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer., Mol Clin Oncol, 2017, 6, 44-48




Heudel, PE ; Fabbro, M ; Roemer-Becuwe, C ; Kaminsky, MC ; Arnaud, A ; Joly, F & al , Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group., Br J Cancer, 2017, 116, 303-309




Hamadou, WS ; Besbes, S ; Mani, R ; Bourdon, V ; Ben Youssef, Y ; Achour, B & al , ARLTS1, potential candidate gene in familial aggregation of hematological malignancies., Bull Cancer, 2017, 104, 123-127




De Castro, J ; González-Larriba, JL ; Vázquez, S ; Massutí, B ; Sanchez-Torres, JM ; Dómine, M & al , Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy., Clin Transl Oncol, 2017, 19, 219-226
 



 

 

PUBLICATIONS 2018

Lire la suite


Hernandez, V ; Vera-S√°nchez, JA ; Vieillevigne, L ; Khamphan, C ; Saez, J , A new method for modelling the tongue-and-groove in treatment planning systems., Phys Med Biol, 2018, 63, 245005




Lazarescu, I ; Dubray, B ; Joulakian, MB ; Blanchard, P ; Chauvet, B ; Mahé, MA & al , Prevalence of burnout, depression and job satisfaction among French senior and resident radiation oncologists., Cancer Radiother, 2018, 22, 784-789




Gravis, G ; Billon, E ; Baldini, C ; Massard, C ; Hilgers, W ; Delva, R & al , Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen., Eur J Cancer, 2018, 104, 236-238




Cottu, P ; D''''Hondt, V ; Dureau, S ; Lerebours, F ; Desmoulins, I ; Heudel, PE & al , Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer., Ann Oncol, 2018, 29, 2334-2340




Antonia, SJ ; Villegas, A ; Daniel, D ; Vicente, D ; Murakami, S ; Hui, R & al , Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC., N Engl J Med, 2018, 379, 2342-2350




Michenot, N ; Rostaing, S ; Baron, L ; Faure, S ; Jovenin, N ; Hubault, P & al , [Opioid switch and change of route of administration in cancer patients treated by morphine]., Bull Cancer, 2018, 105, 1052-1073




Weinberg, I ; Giri, J ; Kolluri, R ; Arcelus, JI ; Falg√°, C ; Soler, S & al , Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry., J Thromb Thrombolysis, 2018, 46, 551-558




van Rhee, F ; Voorhees, P ; Dispenzieri, A ; Fosså, A ; Srkalovic, G ; Ide, M & al , International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease., Blood, 2018, 132, 2115-2124




Fogelman, D ; Cubillo, A ; García-Alfonso, P ; Mirón, MLL ; Nemunaitis, J ; Flora, D & al , Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer., Cancer Med, 2018, 7, 5382-5393




Ninot, G ; Debourdeau, P ; Blanc-Legier, F ; De Crozals, F ; De Rauglaudre, G ; Khouri, S & al , [Supportive care for survivors]., Bull Cancer, 2018, 105, 763-770




Bennouna, J ; Barlesi, F ; Do, P ; Dumont, P ; Cadranel, J ; Debieuvre, D & al , Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)., ESMO Open, 2018, 3, e000394




de Crevoisier, R ; Bayar, MA ; Pommier, P ; Muracciole, X ; Pêne, F ; Dudouet, P & al , Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial., Int J Radiat Oncol Biol Phys, 2018, 102, 1420-1429




Geoffrois, L ; Martin, L ; De Raucourt, D ; Sun, XS ; Tao, Y ; Maingon, P & al , Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial., J Clin Oncol, 2018, , JCO2017762591




Frère, C ; Bournet, B ; Benzidia, I ; Jamelot, M ; Debourdeau, P ; Hij, A & al , [Venous thromboembolism and pancreatic cancer]., J Med Vasc, 2018, 43, 246-254




Tao, Y ; Auperin, A ; Sire, C ; Martin, L ; Khoury, C ; Maingon, P & al , Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial., J Clin Oncol, 2018, , JCO2017762518




Locher, C ; Pourel, N ; Le Caer, H ; Berard, H ; Auliac, JB ; Monnet, I & al , Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06)., Lung Cancer, 2018, 121, 25-29




Coussirou, J ; Debourdeau, A ; Stancu, A ; Jean, C ; Azouza, W ; Chanet, B & al , Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study., Support Care Cancer, 2018, 26, 3827-3834




Aparicio, T ; Bouché, O ; Francois, E ; Retornaz, F ; Barbier, E ; Taieb, J & al , Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer., Eur J Cancer, 2018, 97, 16-24




Aparicio, T ; Bouché, O ; Taieb, J ; Maillard, E ; Kirscher, S ; Etienne, PL & al , Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results., Ann Oncol, 2018, 29, 2270




André, T ; Vernerey, D ; Mineur, L ; Bennouna, J ; Desrame, J ; Faroux, R & al , Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial., J Clin Oncol, 2018, 36, 1469-1477




Chaikh, A ; Ojala, J ; Khamphan, C ; Garcia, R ; Giraud, JY ; Thariat, J & al , Dosimetrical and radiobiological approach to manage the dosimetric shift in the transition of dose calculation algorithm in radiation oncology: how to improve high quality treatment and avoid unexpected outcomes?, Radiat Oncol, 2018, 13, 60




Frikha, M ; Auperin, A ; Tao, Y ; Elloumi, F ; Toumi, N ; Blanchard, P & al , A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)., Ann Oncol, 2018, 29, 731-736




Aparicio, T ; Bouché, O ; Taieb, J ; Maillard, E ; Kirscher, S ; Etienne, PL & al , Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results., Ann Oncol, 2018, 29, 133-138



 


 

PUBLICATIONS 2019

Lire la suite



Jara-Palomares, L ; Alfonso, M ; Maestre, A ; Jimenez, D ; Garcia-Bragado, F ; Font, C & al , Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years., Sci Rep, 2019, 9, 20064




Kaboré, EG ; Guenancia, C ; Vaz-Luis, I ; Di Meglio, A ; Pistilli, B ; Coutant, C & al , Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study., PLoS Med, 2019, 16, e1002989




Ray-Coquard, I ; Pautier, P ; Pignata, S ; Pérol, D ; González-Martín, A ; Berger, R & al , Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer., N Engl J Med, 2019, 381, 2416-2428




Alexia, C ; Cren, M ; Louis-Plence, P ; Vo, DN ; El Ahmadi, Y ; Dufourcq-Lopez, E & al , Polyoxidonium ¬ģ Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer., Front Immunol, 2019, 10, 2693




Figlioli, G ; Bogliolo, M ; Catucci, I ; Caleca, L ; Lasheras, SV ; Pujol, R & al , The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer., NPJ Breast Cancer, 2019, 5, 38




D''''Hondt, V ; Canon, JL ; Roca, L ; Levy, C ; Pierga, JY ; Le Du, F & al , UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup., Eur J Cancer, 2019, 122, 91-100




Lefèvre, JH ; Mineur, L ; Cachanado, M ; Denost, Q ; Rouanet, P ; de Chaisemartin, C & al , Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years'' Follow-up Results of the Greccar-6 Randomized Multicenter Trial., Ann Surg, 2019, 270, 747-754




Gensanne, D ; Hadj Henni, A ; Lauzin, Y ; Clarisse, P ; Thureau, S , [Inter- and intrafraction imaging during stereotactic body radiation therapy: Which solutions for which tumours?], Cancer Radiother, 2019, 23, 891-895




Ferreira, AR ; Di Meglio, A ; Pistilli, B ; Gbenou, AS ; El-Mouhebb, M ; Dauchy, S & al , Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis., Ann Oncol, 2019, 30, 1784-1795




Paz-Ares, L ; Dvorkin, M ; Chen, Y ; Reinmuth, N ; Hotta, K ; Trukhin, D & al , Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial., Lancet, 2019, 394, 1929-1939




Badey, A ; Barateau, A ; Delaby, N ; Fau, P ; Garcia, R ; De Crevoisier, R & al , [Overview of adaptive radiotherapy in 2019: From implementation to clinical use]., Cancer Radiother, 2019, 23, 581-591




Schmid, P ; Zaiss, M ; Harper-Wynne, C ; Ferreira, M ; Dubey, S ; Chan, S & al , Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial., JAMA Oncol, 2019, ,




Riera-Mestre, A ; Mora-Luj√°n, JM ; Trujillo-Santos, J ; Del Toro, J ; Nieto, JA ; Pedrajas, JM & al , Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry., Orphanet J Rare Dis, 2019, 14, 196




Garrel, R ; Mazel, M ; Perriard, F ; Vinches, M ; Cayrefourcq, L ; Guigay, J & al , Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study., Clin Chem, 2019, 65, 1267-1275




Broudic-Guibert, M ; Blay, JY ; Vazquez, L ; Evrard, A ; Karanian, M ; Ta√Įeb, S & al , Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report., J Med Case Rep, 2019, 13, 245




Charton, E ; Bachet, JB ; Hammel, P ; Desramé, J ; Chibaudel, B ; Cohen, R & al , Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial., Cancer Med, 2019, 8, 5079-5088




Köhne, CH ; Karthaus, M ; Mineur, L ; Thaler, J ; Van den Eynde, M ; Gallego, J & al , Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab., Drugs R D, 2019, 19, 267-275




Vieillevigne, L ; Khamphan, C ; Saez, J ; Hernandez, V , On the need for tuning the dosimetric leaf gap for stereotactic treatment plans in the Eclipse treatment planning system., J Appl Clin Med Phys, 2019, 20, 68-77




Rossi, JF ; Céballos, P ; Lu, ZY , Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells., Cancer Commun (Lond), 2019, 39, 34




Pivot, X ; Romieu, G ; Debled, M ; Pierga, JY ; Kerbrat, P ; Bachelot, T & al , 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial., Lancet, 2019, 393, 2591-2598




Bidard, FC ; Kiavue, N ; Ychou, M ; Cabel, L ; Stern, MH ; Madic, J & al , Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial., Cells, 2019, 8,




André, F ; Ciruelos, E ; Rubovszky, G ; Campone, M ; Loibl, S ; Rugo, HS & al , Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer., N Engl J Med, 2019, 380, 1929-1940




Debourdeau, P ; Simonin, C ; Carbasse, C ; Debourdeau, T ; Zammit, C ; Scotté, F , [Primary prophylaxis of venous thromboembolism in ambulatory cancer patients treated with antineoplastic agents]., Rev Med Interne, 2019, 40, 523-532




Joly, F ; Ahmed-Lecheheb, D ; Kalbacher, E ; Heutte, N ; Clarisse, B ; Grellard, JM & al , Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study., Ann Oncol, 2019, 30, 845-852




Le Louedec, F ; Alix-Panabières, C ; Lafont, T ; Allal, BC ; Garrel, R ; Digue, L & al , Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients., Br J Clin Pharmacol, 2019, 85, 1357-1366




Khorana, AA ; Soff, GA ; Kakkar, AK ; Vadhan-Raj, S ; Riess, H ; Wun, T & al , Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer., N Engl J Med, 2019, 380, 720-728




Fuchs, CS ; Shitara, K ; Di Bartolomeo, M ; Lonardi, S ; Al-Batran, SE ; Van Cutsem, E & al , Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial., Lancet Oncol, 2019, 20, 420-435




Boegemann, M ; Khaksar, S ; Bera, G ; Birtle, A ; Dopchie, C ; Dourthe, LM & al , Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study., BMC Cancer, 2019, 19, 60




von Minckwitz, G ; Huang, CS ; Mano, MS ; Loibl, S ; Mamounas, EP ; Untch, M & al , Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer., N Engl J Med, 2019, 380, 617-628




Bennouna, J ; André, T ; Campion, L ; Hiret, S ; Miglianico, L ; Mineur, L & al , Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial., Clin Colorectal Cancer, 2019, 18, e69-e73




Christodoulou, M ; Blackhall, F ; Mistry, H ; Leylek, A ; Knegjens, J ; Remouchamps, V & al , Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial., J Thorac Oncol, 2019, 14, 63-71




Touchefeu, Y ; Guimbaud, R ; Louvet, C ; Dahan, L ; Samalin, E ; Barbier, E & al , Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial., Gastric Cancer, 2019, 22, 577-586




Girard, E ; Eon-Marchais, S ; Olaso, R ; Renault, AL ; Damiola, F ; Dondon, MG & al , Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing., Int J Cancer, 2019, 144, 1962-1974




 

PUBLICATIONS 2020

Lire la suite

 
 
Mineur, L ; François, E ; Plassot, C ; Phelip, JM ; Miglianico, L ; Dourthe, LM & al , PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer., PLoS One, 2020, 15, e0243997



Bertucci, A ; Bertucci, F ; Zemmour, C ; Lerebours, F ; Pierga, JY ; Levy, C & al , PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer., Front Oncol, 2020, 10, 575978




Arnaud, A ; Grenier, J ; Boustany, R ; Kirscher, S ; Mege, A ; de Rauglaudre, G & al , Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer., Support Care Cancer, 2020, ,




Hardy-Bessard, AC ; Brocard, F ; Clatot, F ; Lortholary, A ; You, B ; Grenier, J & al , First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study., Breast, 2020, 54, 256-263




Debourdeau, P ; Belkacémi, M ; Economos, G ; Assénat, E ; Hilgers, W ; Coussirou, J & al , Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancer., BMJ Support Palliat Care, 2020, ,




Lièvre, A ; Turpin, A ; Ray-Coquard, I ; Le Malicot, K ; Thariat, J ; Ahle, G & al , Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)., Eur J Cancer, 2020, 141, 62-81




Blondon, M ; Jimenez, D ; Robert-Ebadi, H ; Del Toro, J ; Lopez-Jimenez, L ; Falga, C & al , Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study., J Thromb Haemost, 2020, ,




Lamy, PJ ; van der Leest, P ; Lozano, N ; Becht, C ; Duboeuf, F ; Groen, HJM & al , Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study., Cancers (Basel), 2020, 12,




Chibaudel, B ; Henriques, J ; Rakez, M ; Brenner, B ; Kim, TW ; Martinez-Villacampa, M & al , Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial., JAMA Netw Open, 2020, 3, e2020425




Jacot, W ; Arnaud, A ; Jarlier, M ; Lefeuvre-Plesse, C ; Dalivoust, P ; Senesse, P & al , Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial., Nutrients, 2020, 12,




Guirimand, F ; Bouleuc, C ; Sahut d''''Izarn, M ; Martel-Samb, P ; Guy-Coichard, C ; Picard, S & al , Development and Validation of the QUALI-PALLI-FAM Questionnaire for Assessing Relatives'' Perception of Quality of Inpatient Palliative Care: A Prospective Cross-Sectional Survey., J Pain Symptom Manage, 2020, ,




Letestu, R ; Dahmani, A ; Boubaya, M ; Baseggio, L ; Campos, L ; Chatelain, B & al , Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia., Leukemia, 2020, ,




Thureau, S ; Briens, A ; Decazes, P ; Castelli, J ; Barateau, A ; Garcia, R & al , PET and MRI guided adaptive radiotherapy: Rational, feasibility and benefit., Cancer Radiother, 2020, 24, 635-644




Mège, A ; Biau, J ; Meyer, E ; Allouache, N ; Guigo, M ; Servagi Vernat, S , [Clinical trials that have changed our practices 2010-2020]., Cancer Radiother, 2020, 24, 612-622




Bachet, JB ; Blons, H ; Hammel, P ; Hariry, IE ; Portales, F ; Mineur, L & al , Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma., Clin Cancer Res, 2020, 26, 5208-5216




Gobbini, E ; Toffart, AC ; Pérol, M ; Assié, JB ; Duruisseaux, M ; Coupez, D & al , Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients., Clin Lung Cancer, 2020, 21, e497-e510




Torres-Lacomba, M ; Navarro-Brazález, B ; Prieto-Gómez, V ; Ferrandez, JC ; Bouchet, JY ; Romay-Barrero, H , Effectiveness of four types of bandages and kinesio-tape for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial., Clin Rehabil, 2020, 34, 1230-1241




Sternberg, CN ; Fizazi, K ; Saad, F ; Shore, ND ; De Giorgi, U ; Penson, DF & al , Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer., N Engl J Med, 2020, 382, 2197-2206




Janoray, G ; Pointreau, Y ; Alfonsi, M ; Sire, C ; Geoffrois, L ; de Raucourt, D & al , Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial., Eur J Cancer, 2020, 133, 86-93




Tao, Y ; Auperin, A ; Blanchard, P ; Alfonsi, M ; Sun, XS ; Rives, M & al , Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial., Radiother Oncol, 2020, 150, 18-25




Fogliata, A ; Cayez, R ; Garcia, R ; Khamphan, C ; Reggiori, G ; Scorsetti, M & al , Technical Note: Flattening filter free beam from Halcyon linac: Evaluation of the profile parameters for quality assurance., Med Phys, 2020, 47, 3669-3674




Pfisterer, J ; Shannon, CM ; Baumann, K ; Rau, J ; Harter, P ; Joly, F & al , Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial., Lancet Oncol, 2020, 21, 699-709




François, E ; Mineur, L ; Deplanque, G ; Laplaige, P ; Smith, D ; Gourgou, S & al , Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (?75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study., Clin Colorectal Cancer, 2020, 19, e100-e109




Pagès, F ; André, T ; Taieb, J ; Vernerey, D ; Henriques, J ; Borg, C & al , Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study., Ann Oncol, 2020, 31, 921-929




Pfister, C ; Harter, V ; Allory, Y ; Radvanyi, F ; Culine, S , Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial., Contemp Clin Trials Commun, 2020, 17, 100536




Palmieri, LJ ; Mineur, L ; Tougeron, D ; Rousseau, B ; Granger, V ; Gornet, JM & al , Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)., Oncologist, 2020, 25, e266-e275




Debourdeau, P ; Cossou-Gbeto, C ; Takam-Sohwe, T ; Laroche, JP , [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?], Bull Cancer, 2020, 107, 224-233




Mavaddat, N ; Antoniou, AC ; Mooij, TM ; Hooning, MJ ; Heemskerk-Gerritsen, BA ; Noguès, C & al , Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers., Breast Cancer Res, 2020, 22, 8




Lievens, Y ; Defourny, N ; Corral, J ; Gasparotto, C ; Grau, C ; Borras, JM , How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement., Lancet Oncol, 2020, 21, e42-e54




Randrian, V ; Adenis, A ; Desrame, J ; Barbier, E ; Di Fiore, F ; Lièvre, A & al , Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study., Dig Liver Dis, 2020, 52, 347-350




Modi, S ; Saura, C ; Yamashita, T ; Park, YH ; Kim, SB ; Tamura, K & al , Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer., N Engl J Med, 2020, 382, 610-621




Perez, T ; Montaleytang, M ; Boisseranc, C ; De Crozals, F ; Darbon, F ; Gérardin, E & al , [Feedback on clinical oncology pharmacy]., Ann Pharm Fr, 2020, 78, 70-75




Penault-Llorca, F ; Kwiatkowski, F ; Arnaud, A ; Levy, C ; Leheurteur, M ; Uwer, L & al , Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict¬ģ (EpClin) use (UCBG 2-14)., Breast, 2020, 49, 132-140




Golemi, I ; Cote, L ; Iftikhar, O ; Brenner, B ; Tafur, A ; Bikdeli, B & al , Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry., J Vasc Surg Venous Lymphat Disord, 2020, 8, 353-359.e1




Cutuli, B ; Lemanski, C ; De Lafontan, B ; Chauvet, MP ; De Lara, CT ; Mege, A & al , Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients., Clin Breast Cancer, 2020, 20, e164-e172




Hammel, P ; Fabienne, P ; Mineur, L ; Metges, JP ; Andre, T ; De La Fouchardiere, C & al , Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial., Eur J Cancer, 2020, 124, 91-101




Sada, PR ; L√≥pez-N√ļ√Īez, JJ ; Samperiz, A ; Soto, MJ ; Pedrajas, JM ; Porras, JA & al , Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry., Angiology, 2020, 71, 131-138




Avnery, O ; Martin, M ; Bura-Riviere, A ; Barillari, G ; Mazzolai, L ; Mahé, I & al , D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry., J Intern Med, 2020, 287, 32-41



Debourdeau, P ; Arvers, P ; Hij, A ; Bennani, H ; Desauw, C ; Falvo, N & al , Factors influencing patient''s perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study., Support Care Cancer, 2020, 28, 287-293
 



 

#DÉCOUVRIR MY WEB ISC


#ACTUALITÉS


PRESENTATION D'UN PASS SANITAIRE

Image actualité

Dans le but de reduire les risques de transmission de la COVID-19, l'accès à ce lieu ...
lire la suite >

CONSIGNES AUX VISITEURS ET ACCOMPAGNANTS

Image actualité

...
lire la suite >

OCTOBRE ROSE 2021

Image actualité

Sainte-Catherine et ses partenaires se mobilisent   ...
lire la suite >

GALA FOURCHETTES ET RUBAN - EDITION 2021

Image actualité

DINER DES CHEFS - EDITION 2021 - PALAIS DES PAPES ...
lire la suite >

Voir toutes les actualités
Site réalisé par www.agence-anonymes.com
Développé et hébergé par www.intrasite.fr